Eli Lilly and Thermo Fisher Scientific have adopted NVIDIA's BioNeMo platform to automate AI-driven drug discovery workflows. The platform delivers pre-trained models for protein structure prediction, small molecule generation, and genomic sequence analysis, replacing manual scientific processes with automated experimental design.
Eli Lilly is integrating BioNeMo's molecular AI capabilities into internal discovery pipelines. Thermo Fisher is embedding the platform within laboratory equipment and software systems, enabling researchers to deploy AI models alongside physical instruments. This positions NVIDIA as middleware infrastructure rather than solely a chip supplier to pharmaceutical operations.
The approach creates recurring software dependencies beyond one-time GPU purchases. As pharmaceutical companies automate research processes globally, BioNeMo becomes embedded in core operations with switching costs. The platform targets both established pharmaceutical companies digitizing legacy research and startups building AI-native discovery models.
BioNeMo provides pre-built components that reduce specialized expertise requirements for deploying AI in laboratory settings. This lowers barriers for smaller biotech firms in emerging markets while offering enterprise-grade tools for multinational pharmaceutical operations. The platform handles adaptation of general AI models to biological data formats and scientific workflows.
NVIDIA's move into domain-specific scientific tooling reflects broader industry patterns where AI infrastructure providers extend beyond general-purpose compute into specialized application layers. These vertical integrations command higher margins and stickier customer relationships across global pharmaceutical and biotech sectors. The biotech AI market spans North American pharmaceutical giants, European research institutions, and Asian biotech startups competing in drug development timelines.
